Aminoalkylindole

Aminoalkylindoles (AAIs) are a family of cannabinergic compound that act as a cannabinoid receptor agonist. They were invented by pharmaceutical company Sterling-Winthrop in the early 1990s as potential non-steroidal anti-inflammatory agents.

Aminoalkylindole are now commonly found in synthetic cannabis designer drugs.

In the United States, the DEA added the aminoalkylindole JWH-200 to Schedule I of the Controlled Substances Act on 1 March 2011 for 12 months.